Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

The Effects of Negative Elements in Environment and Cancer on Female Reproductive System.

Tytuł:
The Effects of Negative Elements in Environment and Cancer on Female Reproductive System.
Autorzy:
Qu J; Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.
Li Y; Department of Gynaecology and Obstetrics, Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Liao S; Department of Gynaecology and Obstetrics, Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. .
Yan J; Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China. .
Źródło:
Advances in experimental medicine and biology [Adv Exp Med Biol] 2021; Vol. 1300, pp. 283-313.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: 1998- : New York : Kluwer Academic/Plenum Publishers
Original Publication: New York, Plenum Press.
MeSH Terms:
Fertility Preservation*
Infertility, Female*
Neoplasms*
Female ; Fertility ; Genitalia, Female ; Humans
References:
Chang SH, et al. Premenopausal factors influencing premature ovarian failure and early menopause. Maturitas. 2007;58(1):19–30. (PMID: 1753141010.1016/j.maturitas.2007.04.00117531410)
Progetto Menopausa Italia Study Group. Premature ovarian failure: frequency and risk factors among women attending a network of menopause clinics in Italy. BJOG. 2003;110(1):59–63. (PMID: 10.1046/j.1471-0528.2003.02129.x)
Freour T, et al. Active smoking compromises IVF outcome and affects ovarian reserve. Reprod Biomed Online. 2008;16(1):96–102. (PMID: 1825205410.1016/S1472-6483(10)60561-518252054)
Peck JD, et al. Lifestyle factors associated with histologically derived human ovarian non-growing follicle count in reproductive age women. Hum Reprod. 2016;31(1):150–7. (PMID: 2649795710.1093/humrep/dev27126497957)
Sobinoff AP, et al. Scrambled and fried: cigarette smoke exposure causes antral follicle destruction and oocyte dysfunction through oxidative stress. Toxicol Appl Pharmacol. 2013;271(2):156–67. (PMID: 2369314110.1016/j.taap.2013.05.00923693141)
Agarwal A, et al. The effects of oxidative stress on female reproduction: a review. Reprod Biol Endocrinol. 2012;10:49. (PMID: 22748101352716810.1186/1477-7827-10-49)
Waziry R, et al. The effects of waterpipe tobacco smoking on health outcomes: an updated systematic review and meta-analysis. Int J Epidemiol. 2017;46(1):32–43. (PMID: 2707576927075769)
Hughes EG, et al. Cigarette smoking and the outcomes of in vitro fertilization: measurement of effect size and levels of action. Fertil Steril. 1994;62(4):807–14. (PMID: 792609210.1016/S0015-0282(16)57009-57926092)
Soares SR, et al. Cigarette smoking affects uterine receptiveness. Hum Reprod. 2007;22(2):543–7. (PMID: 1709551710.1093/humrep/del39417095517)
Nelson TM, et al. Cigarette smoking is associated with an altered vaginal tract metabolomic profile. Sci Rep. 2018;8(1):852. (PMID: 29339821577052110.1038/s41598-017-14943-3)
Meldrum DR, et al. Aging and the environment affect gamete and embryo potential: can we intervene? Fertil Steril. 2016;105(3):548–59. (PMID: 2681224410.1016/j.fertnstert.2016.01.01326812244)
Fisher-Wellman K, Bloomer RJ. Acute exercise and oxidative stress: a 30 year history. Dyn Med. 2009;8:1. (PMID: 19144121264281010.1186/1476-5918-8-1)
Leelarungrayub D, et al. Six weeks of aerobic dance exercise improves blood oxidative stress status and increases interleukin-2 in previously sedentary women. J Bodyw Mov Ther. 2011;15(3):355–62. (PMID: 2166511310.1016/j.jbmt.2010.03.00621665113)
Checa Vizcaino MA, Gonzalez-Comadran M, Jacquemin B. Outdoor air pollution and human infertility: a systematic review. Fertil Steril. 2016;106(4):897–904.e1. (PMID: 2751355310.1016/j.fertnstert.2016.07.111027513553)
Rosen EM, et al. Environmental contaminants and preeclampsia: a systematic literature review. J Toxicol Environ Health B Crit Rev. 2018;21(5):291–319. (PMID: 30582407637404710.1080/10937404.2018.1554515)
Dorea JG. Environmental exposure to low-level lead (Pb) co-occurring with other neurotoxicants in early life and neurodevelopment of children. Environ Res. 2019;177:108641. (PMID: 3142144510.1016/j.envres.2019.10864131421445)
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. (PMID: 2129685510.3322/caac.2010721296855)
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. (PMID: 10.3322/caac.21262)
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. https://doi.org/10.3322/caac.20138 . (PMID: 10.3322/caac.201382223778122237781)
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al., editors. SEER cancer statistics review, 1975–2012. Bethesda, MD: National Cancer Institute; 2015. http://seer.cancer.gov/csr/1975_2012/ , based on November 2014 SEER data submission, posted to the SEER web site.
Martin J, Hamilton B, Sutton P, Menacker F, Kirmeyer S. Births: final data for 2004. Natl Vital Stat Rep. 2006;55:1–101. (PMID: 17432301)
Juan B, Gratacós E. Delayed childbearing: effects on fertility and the outcome of pregnancy. Fetal Diagn Ther. 2011;29(4):263–73. (PMID: 10.1159/000323142)
Armuand GM, Wettergren L, Rodriguez-Wallberg KA, Lampic C. Desire for children, difficulties achieving a pregnancy, and infertility distress 3 to 7 years after cancer diagnosis. Support Care Cancer. 2014;22(10):2805–12. (PMID: 24817617415397310.1007/s00520-014-2279-z)
Hulsbosch S, Koskas M, Tomassetti C, De Sutter P, Wildiers H, Neven P, D'Hooghe T, Amant F. A real-life analysis of reproductive outcome after fertility preservation in female Cancer patients. Gynecol Obstet Investig. 2018;83(2):156–63. (PMID: 10.1159/000478045)
Gorman JR, Malcarne VL, Roesch SC, Madlensky L, Pierce JP. Depressive symptoms among young breast cancer survivors: the importance of reproductive concerns. Breast Cancer Res Treat. 2010;123(2):477–85. (PMID: 20130979288895610.1007/s10549-010-0768-4)
Huyghe E, Sui D, Odensky E, et al. Needs assessment survey to justify establishing a reproductive health clinic at a comprehensive cancer center. J Sex Med. 2009;6(1):149–63. (PMID: 1882332310.1111/j.1743-6109.2008.01005.x)
Tschudin S, Bitzer J. Psychological aspects of fertility preservation in men and women affected by cancer and other life-threatening diseases. Hum Reprod Update. 2009;15:587–97. https://doi.org/10.1093/humupd/dmp015 . (PMID: 10.1093/humupd/dmp01519433413)
Niemasik EE, Letourneau J, Dohan D, Katz A, Melisko M, Rugo H, Rosen M. Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors. J Cancer Surviv. 2012;6:324–32. https://doi.org/10.1007/s11764-012-0227-9 . (PMID: 10.1007/s11764-012-0227-922752834)
Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV. Oktay K; American Society of Clinical Oncology. J Clin Oncol. 2006;24:2917–31. (PMID: 1665164210.1200/JCO.2006.06.5888)
Agarwal A, Said TM. Implications of systemic malignancies on human fertility. Reprod Biomed Online. 2004;9:673–9. (PMID: 1567041910.1016/S1472-6483(10)61779-815670419)
Quintero RB, Helmer A, Huang JQ, et al. Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril. 2010;93(3):865–8. (PMID: 1901356310.1016/j.fertnstert.2008.10.00719013563)
Domingo J, Guillén V, Ayllón Y, et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril. 2012;97(4):930–4. (PMID: 2228396910.1016/j.fertnstert.2012.01.093)
Friedler S, Koc O, Gidoni Y, et al. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril. 2012;97(1):125–33. (PMID: 2207878410.1016/j.fertnstert.2011.10.014)
Pal L, Leykin L, Schifren JL, et al. Malignancy may adversely influence the quality and behaviour of oocytes. Hum Reprod. 1998;13(7):1837–40. (PMID: 974043510.1093/humrep/13.7.1837)
Knopman JM, Noyes N, Talebian S, Krey LC, Grifo JA, Licciardi F. Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril. 2009;91:1476–8. (PMID: 1880420410.1016/j.fertnstert.2008.07.1727)
Quintero RB, Helmer A, Huang JQ, Westphal LM. Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril. 2010;93:865–8. (PMID: 1901356310.1016/j.fertnstert.2008.10.00719013563)
Das M, Shehata F, Moria A, Holzer H, Son WY, Tulandi T. Ovarian reserve, response to gonadotropins, and oocyte maturity in women with malignancy. Fertil Steril. 2011;96:122–5. (PMID: 2157594010.1016/j.fertnstert.2011.04.070)
Moria A, Das M, Shehata F, Holzer H, Son W-Y, Tulandi T. Ovarian reserve and oocyte maturity in women with malignancy undergoing in vitro maturation treatment. Fertil Steril. 2011;95:1621–3. (PMID: 2123642110.1016/j.fertnstert.2010.12.041)
Noyes N, Knopman JM, Long K, Coletta JM, Abu-Rustum NR. Fertility considerations in the management of gynecologic malignancies. Gynecol Oncol. 2011;120(3):326–33. (PMID: 2094325810.1016/j.ygyno.2010.09.012)
Robertson AD, Missmer SA, Ginsburg ES. Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy. Fertil Steril. 2011;95(2):588–91. (PMID: 2054250810.1016/j.fertnstert.2010.04.02820542508)
Almog B, Eldar I, Hasson Y, et al. Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation. Fertil Steril. 2012;98(3):S119. (PMID: 10.1016/j.fertnstert.2012.07.441)
Johnson LN, Dillon KE, Sammel MD, Efymow BL, Mainigi MA, Dokras A, Gracia CR. Response to ovarian stimulation in patients facing gonadotoxic therapy. Reprod Biomed Online. 2013;26:337–44. (PMID: 23415997362108810.1016/j.rbmo.2013.01.003)
Levin I, Almog B. Effect of cancer on ovarian function in patients undergoing in vitro fertilization for fertility preservation: a reappraisal. Curr Oncol. 2013;20:e1–3. (PMID: 23443918355733610.3747/co.20.1193)
Nurudeen SK, Douglas NC, Mahany EL, Sauer MV, Choi JM. Fertility preservation decisions among newly diagnosed oncology patients: a single-center experience. Am J Clin Oncol. 2016;39:154–9. (PMID: 2444158110.1097/COC.000000000000003124441581)
Tsampras N, Roberts SA, Gould D, et al. Ovarian response to controlled ovarian stimulation for fertility preservation before oncology treatment: a retrospective cohort of 157 patients. Eur J Cancer Care. 2018;27(2):e12797. (PMID: 10.1111/ecc.12797)
Decanter C, Robin G, Mailliez A, Sigala J, Morschhauser F, Ramdane N, Devos P, Dewailly D, Leroy-Martin B, Keller L. Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controls. Reprod Biomed Online. 2018;36(5):543–51. (PMID: 2950686110.1016/j.rbmo.2018.01.01629506861)
Visvader JE. Cells of origin in cancer nature. Nature. 2011;469(7330):314–22. (PMID: 2124883810.1038/nature0978121248838)
Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril. 2013;99(6):1476–84. (PMID: 2363534810.1016/j.fertnstert.2013.03.02923635348)
Charlotte S, Marjorie C, Solene D, Christophe S, Nathalie S, Michaël G. Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin’s lymphoma when compared with breast cancer candidates for fertility preservation. J Assist Reprod Genet. 2018;35(1):91–7. (PMID: 10.1007/s10815-017-1059-3)
Kaplan JR, Manuck SB. Ovarian dysfunction, stress, and disease: a primate continuum. ILAR J. 2004;45(2):89–115. (PMID: 1511173010.1093/ilar.45.2.8915111730)
Rosendahl M, Greve T, Andersen CY. The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. J Assist Reprod Genet. 2013;30(1):11–24. (PMID: 2326384110.1007/s10815-012-9912-x23263841)
Bornstein SR, Rutkowski H, Vrezas I. Cytokines and steroidogenesis. Mol Cell Endocrinol. 2004;215(1–2):135–41. (PMID: 1502618610.1016/j.mce.2003.11.02215026186)
Paradisi R, Vicenti R, Macciocca M, Seracchioli R, Rossi S, Fabbri R. High cytokine expression and reduced ovarian reserve in patients with Hodgkin lymphoma or non-Hodgkin lymphoma. Fertil Steril. 2016;106:1176–82. (PMID: 2743020610.1016/j.fertnstert.2016.06.03527430206)
Samir M, Glister C, Mattar D, et al. Follicular expression of pro-inflammatory cytokines tumour necrosis factor-α (TNFα), interleukin 6 (IL6) and their receptors in cattle: TNFα, IL6 and macrophages suppress thecal androgen production in vitro. Reproduction. 2017;154:35–49. (PMID: 2843209110.1530/REP-17-005328432091)
Fabbri R, Pasquinelli G, Magnani V, Arpinati M, Battaglia C, Paradisi R, Venturoli S. Follicle features in adolescent and young adult women with Hodgkin’s disease prior to chemotherapy: a preliminary report. Reprod Biomed Online. 2011;23(6):799–805. (PMID: 2203618810.1016/j.rbmo.2011.07.02022036188)
Alvarez RM, Ramanathan P. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response. Hum Reprod. 2018;33:2051–9. (PMID: 2737035827370358)
Carneiro MM. Stem cells and uterine leiomyomas: what is the evidence? J Brasil Reprod Assist. 2016;20(1):33.
Kim J, Turan V, Oktay K. Long-term safety of Letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab. 2016;101:1364–71. (PMID: 26751194488017110.1210/jc.2015-3878)
Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer. 2012;118(7):1933–9. (PMID: 2185072810.1002/cncr.2640321850728)
Stensheim H, Cvancarova M, Møller B, Fosså SD. Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer. 2011;129:1225–36. (PMID: 2138731110.1002/ijc.2604521387311)
Quinn MM, Cakmak H, Letourneau JM, Cedars MI, Rosen MP. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. 2017; 32(3):568–74.
Azim HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16:427. (PMID: 25436920430322910.1186/s13058-014-0427-5)
Lambertini M, Pinto AC, Ameye L, Jongen L, Del Mastro L, Puglisi F, et al. The prognostic performance of adjuvant! Online and Nottingham prognostic index in young breast cancer patients. Br J Cancer. 2016;115:1471–8. (PMID: 27802449515535910.1038/bjc.2016.359)
Poggio F, Levaggi A, Lambertini M. Chemotherapy-induced premature ovarian failure and its prevention in premenopausal breast cancer patients. Expert Rev Qual Life Cancer Care. 2016;1:5–7. (PMID: 10.1080/23809000.2016.1139458)
Derks-Smeets IAP, van Tilborg TC, van Montfoort A, et al. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. J Assist Reprod Genet. 2017;34:1475–82. (PMID: 28831696569999310.1007/s10815-017-1014-3)
Shapira M, Raanani H, Feldman B, Srebnik N, Dereck-Haim S, Manela D, Brenghausen M, Geva-Lerner L, Friedman E, Levi-Lahad E, Goldberg D. BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. Fertil Steril. 2015;104(5):1162–7. (PMID: 2633513010.1016/j.fertnstert.2015.07.116226335130)
Turan V, Bedoschi G, Emirdar V, Moy F, Oktay K. Ovarian stimulation in patients with cancer: impact of letrozole and BRCA mutations on fertility preservation cycle outcomes. Reprod Sci (Thousand Oaks, CA). 2018;25(1):26–32. (PMID: 10.1177/1933719117728800)
Phillips KA, Collins IM, Milne RL, et al. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Hum Reprod. 2016;31(5):1126–32. (PMID: 27094481484002510.1093/humrep/dew044)
Lawrenz B, Fehm T, Wolff MV, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma—evaluation by using antimüllerian hormone and retrieved oocytes. Fertil Steril. 2012;98(1):141–4. (PMID: 2260789110.1016/j.fertnstert.2012.04.02122607891)
Lekovich J, Lobel ALS, Stewart JD, et al. Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies. J Assist Reprod Genet. 2016;33(5):657–62. (PMID: 26943918487044710.1007/s10815-016-0689-1)
Sonigo C, Comtet M, Duros S, Sifer C, Sermondade N, Grynberg M. Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin’s lymphoma when compared with breast cancer candidates for fertility preservation. J Assist Reprod Genet. 2018;35(1):91–7. (PMID: 2898673410.1007/s10815-017-1059-328986734)
van Dorp W, Van Den Heuvel-Eibrink MM, de Vries AC, Pluijm SM, Visser JA, Pieters R, Laven JS. Decreased serum anti-Müllerian hormone levels in girls with newly diagnosed cancer. Hum Reprod. 2014;29(2):337–42. (PMID: 2434557910.1093/humrep/det44224345579)
Sklavos MM, Stratton P, Giri N, Alter BP, Savage SA, Pinto LA. Reduced serum levels of anti-Müllerian hormone in females with inherited bone marrow failure syndromes. J Clin Endocrinol Metab. 2015;100(2):E197–203. (PMID: 2540550010.1210/jc.2014-283825405500)
Donnez J, Dolmans MM. Preservation of fertility in females with haematological malignancy. Br J Haematol. 2011;154(2):175–84. (PMID: 2156407710.1111/j.1365-2141.2011.08723.x21564077)
Shapira M, Raanani H, Cohen Y, et al. Fertility preservation in young females with hematological malignancies. Acta Haematol. 2014;132(3–4):400–13. (PMID: 2522856610.1159/00036019925228566)
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. (PMID: 10.3322/caac.21387)
Schover LR, Brey K, Lichtin A, Lipschultz LI, Jeha S. Oncologists’ attitudes and practices regarding banking sperm before cancer treatment. J Clin Oncol. 2002;20(7):1890–7. (PMID: 1191924910.1200/JCO.2002.07.17411919249)
Roeca C, Dovey S, Polotsky AJ. Recommendations for assessing ovarian health and fertility potential in survivors of childhood cancer. Maturitas. 2019;122:57–9. (PMID: 3079753110.1016/j.maturitas.2019.01.00930797531)
Taylor JF, Ott MA. Fertility preservation after a cancer diagnosis: a systematic review of adolescents’, parents’, and providers’ perspectives, experiences, and preferences. J Pediatr Adolesc Gynecol. 2016;29(6):585–98. (PMID: 27108230590355310.1016/j.jpag.2016.04.005)
Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–31. (PMID: 1665164210.1200/JCO.2006.06.5888)
Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2009;27(16):2677–85. (PMID: 19364965269039210.1200/JCO.2008.20.1541)
Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14:1. (PMID: 26728489470058010.1186/s12916-015-0545-7)
Green DM, Sklar CA, Boice JD Jr, Mulvihill JJ, Whitton JA, Stovall M, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2374–81. (PMID: 19364956267792310.1200/JCO.2008.21.1839)
Meirow D, Biederman H, Anderson RA, Wallace WH. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol. 2010;53(4):727–39. (PMID: 2104844010.1097/GRF.0b013e3181f96b5421048440)
Van de Loo L, Van den Bergh M, Overbeek A, Van Dijk M, Damen L, et al. Uterine function, pregnancy complications and pregnancy outcomes among female childhood cancer survivors. Fertil Steril. 2019;111:372–80. (PMID: 3069163410.1016/j.fertnstert.2018.10.01630691634)
Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011;205:103–10. (PMID: 21411052511196710.1016/j.ajog.2011.01.025)
Mancini J, Rey D, Preau M, Malavolti L, Moatti JP. Infertility induced by cancer treatment: inappropriate or no information provided to majority of French survivors of cancer. Fertil Steril. 2008;90(5):1616–25. https://doi.org/10.1016/j.fertnstert.2007.08.064 . (PMID: 10.1016/j.fertnstert.2007.08.0641805400418054004)
Peate M, et al. The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review. Breast Cancer Res Treat. 2009;116(2):215–23. (PMID: 1939096210.1007/s10549-009-0401-619390962)
Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364:1405–10. (PMID: 1548821510.1016/S0140-6736(04)17222-X15488215)
Wallace WHB, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol. 2005;6:209–18. (PMID: 1581161610.1016/S1470-2045(05)70092-9)
Codacci-Pisanelli G, Del Pup L, Del Grande M, et al. Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients. Crit Rev Oncol Hematol. 2017;113:90–6. (PMID: 2842752810.1016/j.critrevonc.2017.03.009)
Wo J, Viswanathan A. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys. 2009;5:1304–12. (PMID: 10.1016/j.ijrobp.2008.12.016)
Salama M, Winkler K, Murach KF, Seeber B, Ziehr SC, Wildt L. Female fertility loss and preservation: threats and opportunities. Ann Oncol. 2013;24:598–608. (PMID: 2312912110.1093/annonc/mds514)
Lawrenz B, Mahajan N, Fatemi HM. The effects of cancer therapy on women’s fertility: what do we know now? Future Oncol. 2016;12:1721–9. (PMID: 2695622810.2217/fon-2015-0004)
Alvarez RM, Vazquez-Vicente D. Fertility sparing treatment in borderline ovarian tumours. E Cancer Medical Sci. 2015;9:507.
Balachandren N, Davies M. Fertility, ovarian reserve and cancer. Maturitas. 2017;105:64–8. (PMID: 2878987710.1016/j.maturitas.2017.07.013)
Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Oktay K. American society of clinical oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917–31. (PMID: 1665164210.1200/JCO.2006.06.5888)
Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N. How do chemotherapeutic agents damage the ovary? Hum Reprod Update. 2012;18:525–35. (PMID: 2264750410.1093/humupd/dms022)
Behringer K, et al. Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2005;23(30):7555. (PMID: 1623452110.1200/JCO.2005.08.138)
Balcerek M, et al. Suspected infertility after treatment for leukemia and solid tumors in childhood and adolescence. Dtsch Rztebl Int. 2012;109(7):126–31.
Bodurka DC, Sun CC. Sexual function after gynecologic cancer. Obstet Gynecol Clin N Am. 2006;33:621–30. (PMID: 10.1016/j.ogc.2006.09.006)
Abbott-Anderson K, Kwekkeboom KL. A systematic review of sexual concerns reported by gynecological cancer survivors. Gynecol Oncol. 2012;124:477–89. (PMID: 2213437510.1016/j.ygyno.2011.11.030)
Pereira N, Hancock K, Cordeiro CN, et al. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes? Gynecol Endocrinol. 2016;32(10):823–6. (PMID: 2711405110.1080/09513590.2016.1177013)
Irtan S, Orbach D, Helfre S, Sarnacki S. Ovarian transposition in prepubescent and adolescent girls with cancer. Lancet Oncol. 2013;14(13):e601–8. (PMID: 2427513310.1016/S1470-2045(13)70288-2)
Jensen PT, Froeding LP. Pelvic radiotherapy and sexual function in women. Transl Androl Urol. 2015;4(2):186–205. (PMID: 268168244708128)
Biedka M, Kuźba-Kryszak T, Nowikiewicz T, Żyromska A. Fertility impairment in radiotherapy. Contemp Oncol (Pozn). 2016;20(3):199–204.
Duncan FE, Zelinski M, Gunn AH, et al. Ovarian tissue transport to expand access to fertility preservation: from animals to clinical practice. Reproduction. 2016;152(6):R201. (PMID: 27492079508805510.1530/REP-15-0598)
Gao H, Yang BJ, Li N, Feng LM, Shi XY, Zhao WH, et al. Bisphenol A and hormone-associated cancers: current progress and perspectives. Medicine (Baltimore). 2015;94(1):e211. (PMID: 10.1097/MD.0000000000000211)
Chieng PU, Huang TS, Chang CC, Chong PN, Tien RD, Su CT. Reduced hypothalamic blood flow after radiation treatment of nasopharyngeal cancer: SPECT studies in 34 patients. Am J Neuroradiol. 1991;12:661–5. (PMID: 1882739)
Hochberg Z, Kuten A, Hertz P, Tatcher M, Kedar A, Benderly A. The effect of single-dose radiation on cell survival and growth hormone secretion by rat anterior pituitary cells. Radiat Res. 1983;94:508–12. (PMID: 685678710.2307/35759086856787)
Robinson IC, Fairhall KM, Hendry JH, Shalet SM. Differential radiosensitivity of hypothalamopituitary function in the young adult rat. J Endocrinol. 2001;169:519–26. (PMID: 1137512210.1677/joe.0.169051911375122)
Marci R, Mallozzi M, Di Benedetto L, et al. Radiations and female fertility. Reprod Biol Endocrinol. 2018;16(1):112. (PMID: 30553277629531510.1186/s12958-018-0432-0)
Muñoz M, Santaballa A, Seguí MA, Beato C, de la Cruz S, Espinosa J, et al. SEOM clinical guideline of fertility preservation and reproduction in cancer patients (2016). Clin Transl Oncol. 2016;18(12):1229–36. (PMID: 27896641513825110.1007/s12094-016-1587-9)
Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod. 2003;18(1):117–21. (PMID: 1252545110.1093/humrep/deg01612525451)
Damewood MD, Grochow LB. Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril. 1986;45(4):443–59. (PMID: 308268010.1016/S0015-0282(16)49268-X3082680)
Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91(5):1723–8. (PMID: 1649269010.1210/jc.2006-002016492690)
Rodriguez-Wallberg KA, Oktay K. Fertility preservation during cancer treatment: clinical guidelines. Cancer Manag Res. 2014;6:105–17. (PMID: 246239913949560)
Green DM, Sklar CA, Boice JD, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2374–81. (PMID: 19364956267792310.1200/JCO.2008.21.1839)
Wallace WHB. Oncofertility and preservation of reproductive capacity in children and young adults. Cancer. 2011;117(Suppl):2301–10. (PMID: 2152375010.1002/cncr.2604521523750)
Levy MJ, Stillman RJ. Reproductive potential in survivors of childhood malignancy. Pediatrician. 1991;18(1):61–70. (PMID: 19838631983863)
Thibaud E, et al. Ovarian function after bone marrow transplantation during childhood. Bone Marrow Transplant. 1998;21(3):287–90. (PMID: 948965210.1038/sj.bmt.17010759489652)
Beurden MV, Schuster-Uitterhoeve ALJ, Lammes FB. Feasibility of transposition of the ovaries in the surgical and radiotherapeutical treatment of cervical cancer. Eur J Surg Oncol. 1990;16(2):141–6. (PMID: 23234102323410)
Mahajan N. Fertility preservation in female cancer patients: an overview. J Hum Reprod Sci. 2015;8(1):3–13. (PMID: 25838742438137910.4103/0974-1208.178632)
Teh WT, Stern C, Chander S, Hickey M. The impact of uterine radiation on subsequent fertility and pregnancy outcomes. Biomed Res Int. 2014;2014:482968. (PMID: 25165706414012410.1155/2014/482968)
Stephen MD, Zage PE, Waguespack SG. Gonadotropin-dependent precocious puberty: neoplastic causes and endocrine considerations. Int J Pediatr Endocrinol. 2011;2011(1):184502. (PMID: 21603196321280110.1155/2011/184502)
Chemaitilly W, Sklar CA. Endocrine complications in longterm survivors of childhood cancers. Endocr Relat Cancer. 2010;17:141–59. (PMID: 10.1677/ERC-10-0002)
Follin C, Erfurth EM. Long-term effect of cranial radiotherapy on pituitary-hypothalamus area in childhood acute lymphoblastic leukemia survivors. Curr Treat Options in Oncol. 2016;17(9):50. (PMID: 10.1007/s11864-016-0426-0)
Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin’s disease. Cancer. 1983;52(6):988–93. (PMID: 641132110.1002/1097-0142(19830915)52:6<988::AID-CNCR2820520610>3.0.CO;2-66411321)
Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001;7(6):535–43. (PMID: 1172786110.1093/humupd/7.6.53511727861)
Duffy C, Allen S. Medical and psychosocial aspects of fertility after cancer. Cancer J. 2009;15(1):27–33. (PMID: 19197170271971710.1097/PPO.0b013e3181976602)
Marcello MF, Nuciforo G, Romeo R, et al. Structural and ultrastructural study of the ovary in childhood leukemia after successful treatment. Cancer. 1990;66(10):2099–104. (PMID: 222476410.1002/1097-0142(19901115)66:10<2099::AID-CNCR2820661010>3.0.CO;2-3)
Bar-Joseph H, Ben-Aharon I, Tzabari M, Tsarfaty G, Stemmer SM, Shalgi R. In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS One. 2011;6(9):e23492. (PMID: 21931602317028610.1371/journal.pone.0023492)
De Haes H, Olschewski M, Kaufmann M, Schumacher M, Jonat W, Sauerbrei W. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(24):4510–6. (PMID: 10.1200/JCO.2003.11.064)
Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol. 2003;21(22):4184–93. (PMID: 1461544610.1200/JCO.2003.04.196)
Ghidoni R, Boccardi M, Benussi L, Testa C, Villa A, Pievani M, Gigola L, Sabattoli F, Barbiero L, Frisoni GB, Binetti G. Effects of estrogens on cognition and brain morphology: involvement of the cerebellum. Maturitas. 2006;54:222–8. (PMID: 1634382810.1016/j.maturitas.2005.11.002)
Nystedt M, Berglund G, Bolund C, Fornander T, Rutqvist LE. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol. 2003;21(9):1836–44. (PMID: 1272126110.1200/JCO.2003.04.024)
Tchen N, Juffs HG, Downie FP, Yi QL, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(22):4175–83. (PMID: 10.1200/JCO.2003.01.119)
Algarroba GN, Sanfilippo JS, Valli-Pulaski H. Female fertility preservation in the pediatric and adolescent cancer patient population. Best practice & research. Clin Obstet Gynaecol. 2018;48:147–57.
Žulpaitė R, Bumbulienė Ž. Reproductive health of female childhood cancer survivors. Ginekol Pol. 2018;89(5):280–6. (PMID: 3008448110.5603/GP.a2018.0048)
Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging (Albany NY). 2011;3(8):782–93. (PMID: 10.18632/aging.100363)
Codacci-Pisanelli G, Del Pup L, Del Grande M, Peccatori FA. Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients. Crit Rev Oncol Hematol. 2017;113:90–6. (PMID: 2842752810.1016/j.critrevonc.2017.03.009)
Lopes F, Smith R, Anderson RA, et al. Docetaxel induces moderate ovarian toxicity in mice, primarily affecting granulosa cells of early growing follicles. Mol Hum Reprod. 2014;20(10):948–59. (PMID: 25080441417217310.1093/molehr/gau057)
Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016;12(20):2333–44. (PMID: 27402553506613410.2217/fon-2016-0176)
Apperley J. Issues of imatinib and pregnancy outcome. J Natl Compr Cancer Netw. 2009;7(10):1050–8. (PMID: 10.6004/jnccn.2009.0069)
Gosden RG. Fertility preservation: definition, history, and prospect. Semin Reprod Med. 2009;27(6):433–7. (PMID: 1980651010.1055/s-0029-1241051)
Loren AW, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10. (PMID: 23715580532108310.1200/JCO.2013.49.2678)
De Vos M, Smitz J, Woodruff TK. Fertility preservation 2 fertility preservation in women with cancer. Lancet. 2014;384(9950):1302–10. (PMID: 25283571427006010.1016/S0140-6736(14)60834-5)
Donnez J, Dolmans M-M. Fertility preservation in women. N Engl J Med. 2017;377(17):1657–65. (PMID: 2906955810.1056/NEJMra1614676)
Bower B, Quinn GP. Fertility preservation in cancer patients: ethical considerations. Adv Exp Med Biol. 2012;732:187–96. (PMID: 2221026210.1007/978-94-007-2492-1_15)
Kumar A, et al. Fertility risk discussions in young patients diagnosed with colorectal cancer. Curr Oncol (Toronto, ON). 2012;19(3):155–9.
Scanlon M, et al. Patient satisfaction with physician discussions of treatment impact on fertility, menopause and sexual health among pre-menopausal women with cancer. J Cancer. 2012;3:217–25. (PMID: 22606211335441710.7150/jca.4408)
Maltaris T, et al. The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol. 2007;130(2):148–55. (PMID: 1697928010.1016/j.ejogrb.2006.08.006)
Knight LJ, et al. Obstetric management following fertility-sparing radical vaginal trachelectomy for cervical cancer. J Obstet Gynaecol. 2010;30(8):784–9. (PMID: 2112611310.3109/01443615.2010.509826)
Leitao MM Jr, Chi DS. Fertility-sparing options for patients with gynecologic malignancies. Oncologist. 2005;10(8):613–22. (PMID: 1617728510.1634/theoncologist.10-8-613)
Wright JD, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer. 2009;115(18):4118–26. (PMID: 1967044610.1002/cncr.24461)
Raju SK, et al. Fertility-sparing surgery for early cervical cancer-approach to less radical surgery. Int J Gynecol Cancer. 2012;22(2):311–7. (PMID: 2223738110.1097/IGC.0b013e3182370f51)
Rob L, Skapa P, Robova H. Fertility-sparing surgery in patients with cervical cancer. Lancet Oncol. 2011;12(2):192–200. (PMID: 2061973710.1016/S1470-2045(10)70084-X)
Weinberg LE, Rodriguez G, Hurteau JA. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. J Surg Oncol. 2010;101(4):334–43. (PMID: 2018706910.1002/jso.21482)
Chinese Anti-Cancer Association, C.o.B.C.S. Diagnosis and treatment for breast cancer: Chinese anti-Cancer association guideline update. China Oncol. 2015;09:692–754.
Oktem O, et al. Ovarian and uterine functions in female survivors of childhood cancers. Oncologist. 2018;23(2):214–24. (PMID: 2915837010.1634/theoncologist.2017-0201)
Terenziani M, et al. Oophoropexy: a relevant role in preservation of ovarian function after pelvic irradiation. Fertil Steril. 2009;91(3):935.e15–6. (PMID: 10.1016/j.fertnstert.2008.09.029)
Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist. 2007;12(9):1044–54. (PMID: 1791407410.1634/theoncologist.12-9-1044)
Behringer K, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol. 2010;21(10):2052–60. (PMID: 2030503410.1093/annonc/mdq066)
Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online. 2010;20(6):783–8. (PMID: 20382080355782010.1016/j.rbmo.2010.03.004)
Del Mastro L, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269–76. (PMID: 21771987)
Munster PN, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30(5):533–8. (PMID: 22231041329555510.1200/JCO.2011.34.6890)
Pantanowitz L, Prefontaine M, Hunt JP. Cholelithiasis of the ovary after laparoscopic cholecystectomy: a case report. J Reprod Med. 2007;52(10):968–70. (PMID: 17977178)
Kim YB, et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer. 1997;79(2):320–7. (PMID: 901010510.1002/(SICI)1097-0142(19970115)79:2<320::AID-CNCR15>3.0.CO;2-2)
Gunderson CC, et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477–82. (PMID: 2224571110.1016/j.ygyno.2012.01.003)
Kaku T, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett. 2001;167(1):39–48. (PMID: 1132309710.1016/S0304-3835(01)00462-1)
Mitwally MFM, Casper RF. Single-dose administration of an aromatase inhibitor for ovarian stimulation. Fertil Steril. 2005;83(1):229–31. (PMID: 1565291810.1016/j.fertnstert.2004.07.952)
Fatum M, McVeigh E, Child T. The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate. Hum Fertil. 2013;16(4):235–40. (PMID: 10.3109/14647273.2013.800650)
Donnez J, Dolmans M-M. Fertility preservation in women. Nat Rev Endocrinol. 2013;9(12):735–49. (PMID: 2416600010.1038/nrendo.2013.205)
Kim SS, et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet. 2012;29(6):465–8. (PMID: 22648282337004510.1007/s10815-012-9786-y)
Cobo A, et al. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105(3):755–764.e8. (PMID: 2668842910.1016/j.fertnstert.2015.11.027)
Shi Y, et al. Transfer of fresh versus frozen embryos in ovulatory women. N Engl J Med. 2018;378(2):126–36. (PMID: 2932064610.1056/NEJMoa1705334)
Chen Z-J, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med. 2016;375(6):523–33. (PMID: 2750910110.1056/NEJMoa1513873)
Rienzi L, et al. Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017;23(2):139–55. (PMID: 27827818)
Metzger ML, et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol. 2013;31(9):1239–47. (PMID: 23382474450083710.1200/JCO.2012.43.5511)
Chian RC, Uzelac PS, Nargund G. In vitro maturation of human immature oocytes for fertility preservation. Fertil Steril. 2013;99(5):1173–81. (PMID: 2343351510.1016/j.fertnstert.2013.01.141)
Green DM, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2374–81. (PMID: 19364956267792310.1200/JCO.2008.21.1839)
Wallace WH, et al. Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation. Lancet Oncol. 2014;15(10):1129–36. (PMID: 25130994415337510.1016/S1470-2045(14)70334-1)
Jadoul P, et al. Efficacy of ovarian tissue cryopreservation for fertility preservation: lessons learned from 545 cases. Hum Reprod. 2017;32(5):1046–54. (PMID: 2833322810.1093/humrep/dex040)
Donnez J, et al. Ovarian tissue cryopreservation and transplantation: a review. Hum Reprod Update. 2006;12(5):519–35. (PMID: 1684981710.1093/humupd/dml032)
Meirow D, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod. 2008;23(5):1007–13. (PMID: 1834456310.1093/humrep/den055)
Dolmans M-M, et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116(16):2908–14. (PMID: 2059551710.1182/blood-2010-01-265751)
Rosendahl M, et al. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril. 2010;94(6):2186–90. (PMID: 2010061910.1016/j.fertnstert.2009.11.032)
Amiot C, et al. Minimal residual disease detection of leukemic cells in ovarian cortex by eight-color flow cytometry. Hum Reprod. 2013;28(8):2157–67. (PMID: 2363355210.1093/humrep/det126)
Soares M, et al. Evaluation of a human ovarian follicle isolation technique to obtain disease-free follicle suspensions before safely grafting to cancer patients. Fertil Steril. 2015;104(3):672–80. (PMID: 2609513410.1016/j.fertnstert.2015.05.021)
Kuleshova L, et al. Birth following vitrification of a small number of human oocytes: case report. Hum Reprod. 1999;14(12):3077–9. (PMID: 1060109910.1093/humrep/14.12.3077)
Amorim CA, et al. Vitrification as an alternative means of cryopreserving ovarian tissue. Reprod Biomed Online. 2011;23(2):160–86. (PMID: 2167665310.1016/j.rbmo.2011.04.005)
Sanfilippo S, et al. Vitrification of human ovarian tissue: a practical and relevant alternative to slow freezing. Reprod Biol Endocrinol. 2015;13:67. (PMID: 26109179448098910.1186/s12958-015-0065-5)
Shi Q, et al. Vitrification versus slow freezing for human ovarian tissue cryopreservation: a systematic review and meta-analysis. Sci Rep. 2017;7(1):8538. (PMID: 28819292556114110.1038/s41598-017-09005-7)
Hudson JN, et al. New promising strategies in oncofertility. Expert Rev Qual Life Cancer Care. 2017;2(2):67–78. (PMID: 28959743561240510.1080/23809000.2017.1308808)
Luyckx V, et al. A new step toward the artificial ovary: survival and proliferation of isolated murine follicles after autologous transplantation in a fibrin scaffold. Fertil Steril. 2014;101(4):1149–56. (PMID: 2446205910.1016/j.fertnstert.2013.12.025)
Mouloungui E, et al. A protocol to isolate and qualify purified human preantral follicles in cases of acute leukemia, for future clinical applications. J Ovarian Res. 2018;11(1):4. (PMID: 29304838575635910.1186/s13048-017-0376-6)
Truman AM, Tilly JL, Woods DC. Ovarian regeneration: the potential for stem cell contribution in the postnatal ovary to sustained endocrine function. Mol Cell Endocrinol. 2017;445:74–84. (PMID: 2774399010.1016/j.mce.2016.10.01227743990)
Moore HCF, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923–32. (PMID: 25738668440523110.1056/NEJMoa1413204)
Soares M, et al. Eliminating malignant cells from cryopreserved ovarian tissue is possible in leukaemia patients. Br J Haematol. 2017;178(2):231–9. (PMID: 2841941210.1111/bjh.1465728419412)
Johnson J, et al. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004;428(6979):145–50. (PMID: 1501449210.1038/nature0231615014492)
Hummitzsch K, et al. Stem cells, progenitor cells, and lineage decisions in the ovary. Endocr Rev. 2015;36(1):65–91. (PMID: 2554163510.1210/er.2014-107925541635)
Telfer EE, Albertini DF. The quest for human ovarian stem cells. Nat Med. 2012;18(3):353–4. (PMID: 2239569910.1038/nm.269922395699)
Horan CJ, Williams SA. Oocyte stem cells: fact or fantasy? Reproduction. 2017;154(1):R23–35. (PMID: 2838952010.1530/REP-17-000828389520)
Castrillon DH, et al. The human VASA gene is specifically expressed in the germ cell lineage. Proc Natl Acad Sci U S A. 2000;97(17):9585–90. (PMID: 109202021690810.1073/pnas.160274797)
Zou K, et al. Production of offspring from a germline stem cell line derived from neonatal ovaries. Nat Cell Biol. 2009;11(5):631–6. (PMID: 1936348510.1038/ncb186919363485)
White YAR, et al. Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women. Nat Med. 2012;18(3):413–21. (PMID: 22366948329696510.1038/nm.2669)
Hayashi K, et al. Offspring from oocytes derived from in vitro primordial germ cell-like cells in mice. Science. 2012;338(6109):971–5. (PMID: 2304229510.1126/science.122688923042295)
Hayashi K, et al. Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells. Cell. 2011;146(4):519–32. (PMID: 2182016410.1016/j.cell.2011.06.05221820164)
Jain KK. Nanotechnology-based drug delivery for cancer. Technol Cancer Res Treat. 2005;4(4):407–16. (PMID: 1602905910.1177/15330346050040040816029059)
Ahn RW, et al. Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo. PLoS One. 2013;8(3):e58491. (PMID: 23526987360396810.1371/journal.pone.0058491)
Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet. 2007;8(8):573–87. (PMID: 17607305709762710.1038/nrg2141)
Bouard D, Alazard-Dany D, Cosset FL. Viral vectors: from virology to transgene expression. Br J Pharmacol. 2009;157(2):153–65. (PMID: 18776913262964710.1038/bjp.2008.349)
Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm. 2009;6(3):659–68. (PMID: 1926745210.1021/mp900015y)
Love KT, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A. 2010;107(5):1864–9. (PMID: 20080679280474210.1073/pnas.0910603106)
Kaneda Y. Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool. Expert Opin Drug Deliv. 2010;7(9):1079–93. (PMID: 2071602010.1517/17425247.2010.510511)
Vader P, Breakefield XO, Wood MJA. Extracellular vesicles: emerging targets for cancer therapy. Trends Mol Med. 2014;20(7):385–93. (PMID: 24703619408276010.1016/j.molmed.2014.03.002)
Zhen Z, et al. Ferritins as nanoplatforms for imaging and drug delivery. Expert Opin Drug Deliv. 2014;11(12):1913–22. (PMID: 25070839488563710.1517/17425247.2014.941354)
He D, Marles-Wright J. Ferritin family proteins and their use in bionanotechnology. New Biotechnol. 2015;32(6):651–7. (PMID: 10.1016/j.nbt.2014.12.006)
Muller LK, Landfester K. Natural liposomes and synthetic polymeric structures for biomedical applications. Biochem Biophys Res Commun. 2015;468(3):411–8. (PMID: 2631526610.1016/j.bbrc.2015.08.088)
Li L, Zhang L, Knez M. Comparison of two endogenous delivery agents in cancer therapy: Exosomes and ferritin. Pharmacol Res. 2016;110:1–9. (PMID: 2715724910.1016/j.phrs.2016.05.006)
Tahover E, Patil YP, Gabizon AA. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes. Anti-Cancer Drugs. 2015;26(3):241–58. (PMID: 2541565610.1097/CAD.0000000000000182)
Contributed Indexing:
Keywords: Female fertility; Fertility preservation; Iatrogenic factors; Lifestyle-related risk factors; Occupational risk factors
Entry Date(s):
Date Created: 20210201 Date Completed: 20210215 Latest Revision: 20210215
Update Code:
20240104
DOI:
10.1007/978-981-33-4187-6_13
PMID:
33523439
Czasopismo naukowe
With the development of human society, factors that contribute to the impairment of female fertility is accumulating. Lifestyle-related risk factors, occupational risk factors, and iatrogenic factors, including cancer and anti-cancer treatments, have been recognized with their negative effects on the function of female reproductive system. However, the exact influences and their possible mechanism have not been elucidated yet. It is impossible to accurately estimate the indexes of female fertility, but many researchers have put forward that the general fertility has inclined through the past decades. Thus the demand for fertility preservation has increased more and more dramatically. Here we described some of the factors which may influence female reproductive system and methods for fertility preservation in response to female infertility.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies